Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8353424 | 0.82 | SIGMAR1 (0.50) | SIGMAR1OPRM1OPRD1ALDH1A1TSHR | |
| SCHEMBL427422 | 0.81 | SIGMAR1 (0.49) | SIGMAR1OPRM1OPRD1ALDH1A1TSHR | |
| SCHEMBL427423 | 0.78 | KCNJ1 (0.55) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13662563 | 0.74 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL25039185 | 0.73 | ALDH1A1 (0.55) | SIGMAR1OPRM1OPRD1ALDH1A1TSHR | |
| SCHEMBL14515341 | 0.73 | ALDH1A1 (0.45) | SIGMAR1OPRM1OPRD1ALDH1A1TSHR | |
| SCHEMBL19623616 | 0.71 | ALDH1A1 (0.42) | ALDH1A1TSHRTP53MEN1KMT2A | |
| SCHEMBL19882292 | 0.71 | CA12 (0.62) | SIGMAR1ALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL11629767 | 0.69 | GAA (0.51) | SIGMAR1OPRM1OPRD1ALDH1A1TSHR | |
| SCHEMBL19623807 | 0.69 | NPC1 (0.51) | ALDH1A1TSHRMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | SIGMAR1 1841/4885OPRM1 894/4885OPRD1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.